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Tau is a microtubule-associated protein responsible mainly for stabilizing the neuronal
microtubule network in the brain. Under normal conditions, tau is highly soluble and
adopts an “unfolded” conformation. However, it undergoes conformational changes
resulting in a less soluble form with weakened microtubule stabilizing properties.
Altered tau forms characteristic pathogenic inclusions in Alzheimer’s disease and related
tauopathies. Although, tau hyperphosphorylation is widely considered to be the major
trigger of tau malfunction, tau undergoes several post-translational modifications at lysine
residues including acetylation, methylation, ubiquitylation, SUMOylation, and glycation.
We are only beginning to define the site-specific impact of each type of lysine modification
on tau biology as well as the possible interplay between them, but, like phosphorylation,
these modifications are likely to play critical roles in tau’s normal and pathobiology. This
review summarizes the latest findings focusing on lysine post-translational modifications
that occur at both endogenous tau protein and pathological tau forms in AD and other
tauopathies. In addition, it highlights the significance of a site-dependent approach of
studying tau post-translational modifications under normal and pathological conditions.
Keywords: tau, acetylation, methylation, ubiquitylation, SUMOylation, glycation, paired helical filaments,
tauopathies
INTRODUCTION
Neurodegenerative diseases of the central nervous system are characterized by selective loss
of synapses and neurons, glial activation, progressive irreversible neural dysfunction, cognitive
impairment and eventually death (Verkhratsky et al., 2014; Kovacs, 2016).Many neurodegenerative
diseases are also known as conformational diseases- or proteinopathies-due to the presence of
pathological forms of proteins that accumulate and deposit in the brain (Carrell and Lomas,
1997). For this reason, it has been assumed that the aggregation of misfolded proteins is the
molecular cause of neurodegeneration. Proteins participating in aggregates lack their normal
tertiary structure and, hence, they are incapable of serving their typical functions in living
cells. The aberrantly-folded forms may also acquire a novel, neurotoxic role (Ballatore et al.,
2007). A common class of neurodegenerative diseases includes the disorders associated with the
filamentous inclusions of tau aggregates in nerve cells and glia, which are known collectively as
tauopathies (Spillantini et al., 1997; Ferrer et al., 2014). One of the main pathological hallmarks
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of Alzheimer’s disease (AD) is the intraneuronal accumulation of
neurofibrillary tangles (NFTs) consisting of misfolded tau protein
and, therefore, AD is considered to be partly a tauopathy and
is one of the most widely studied. Other tauopathies include
progressive supranuclear palsy, frontotemporal dementia with
parkinsonism-17, corticobasal degeneration, argyrophilic grain
disease, Pick’s disease and Huntington’s disease (Hernandez and
Avila, 2007; Gratuze et al., 2016).
Tau protein is a microtubule-associated protein (MAP)
expressed abundantly in neurons and, to a lesser extent,
in astrocytes and oligodendrocytes. In neurons, tau localizes
predominantly to the axonal cytoplasm, but it can also be
found in the nucleus and dendrites (Binder et al., 1985; Migheli
et al., 1988; Loomis et al., 1990). Tau is responsible mainly
for microtubule assembly and stabilization, thus maintaining
the normal morphology of the neuronal cells and enabling
axonal transport. Tau may also be involved in other activities
such as neurogenesis and iron export (Lei et al., 2012; Pallas-
Bazarra et al., 2016). It is encoded by the MAPT gene,
which includes 16 exons located on the human chromosome
17 (Neve et al., 1986; Lee et al., 1988). Based on protein
structure, tau can be divided into four regions: (i) a N-terminal
projection region that protrudes from the microtubules to
which tau is bound and is responsible for interacting with
other, non-microtubular partners; (ii) a proline-rich region
that contains seven PXXP motifs, which serve as binding
sites for signaling proteins; (iii) a microtubule-binding domain
(MBD) that contains three or four repeat regions, R1, R2,
R3, and R4, which are essential for binding to microtubules
through their conserved KXGS motifs, and the flanking
regions between them; (iv) a C-terminal region (Figure 1A;
Mandelkow et al., 1995). There is heterogeneity at the level of
transcription due to alternative splicing of exon 10, resulting
in the generation of two different tau isoforms; these isoforms
are known as 3R or 4R depending on whether they contain
three or four repeat regions within the MBD (Lee et al.,
1989).
Under normal conditions, tau is highly soluble and is classed
as an intrinsically disordered protein. It is believed to have little
tendency for aggregation in this intrinsically disordered state
(Schweers et al., 1994; Mukrasch et al., 2009), however, tau can
undergo conformational changes resulting in altered physical and
chemical properties, including a decrease of solubility. Thereby,
conformationally-stable insoluble structures are formed as tau
assembles into higher-polymerized aggregates that differ between
different tauopathies (Yoshida, 2006). In AD, tau lesions include
neurofibrillary tangles (NFTs) in neuronal cell bodies, neuropil
threads in neurites and dystrophic neurites in neuritic plaques; in
electron microscopy, tau assemblies form mainly paired helical
filaments (PHFs) that consist of both 3R and 4R isoforms
(Figure 1B). In contrast, 3R or 4R tau isoforms are preferentially
accumulated in a variety of tauopathies, such as progressive
supranuclear palsy and Pick’s disease (Dickson et al., 2011).
The processes underpinning the formation of tau aggregates
are not completely understood, but appear to involve a variety
of post-translational modifications occurring at many sites
throughout tau, including phosphorylation, O-Glc-NAcylation,
glycation, nitration, acetylation, methylation, SUMOylation,
ubiquitylation, oxidation, and truncation (Martin et al., 2011).
Since the phosphorylation state of tau controls its intrinsic
affinity for microtubules and given the fact that aggregated tau
species have been shown to be hyperphosphorylated at several
serine, threonine and tyrosine residues, numerous studies have
focused on exploring tau phosphorylation (Grundke-Iqbal et al.,
1986; Williamson et al., 2002). Conversely, tau modifications
that extend to lysine residues have not yet been analyzed as
extensively, but it is likely that they might be as important
as phosphorylation in dictating the biophysical properties of
tau, because they profoundly alter the charge of the protein.
This review gives an overview of the latest findings concerning
the lysine-directed tau post-translational modifications, which
include acetylation, methylation, ubiquitylation, SUMOylation
and glycation, and discusses the impact on tau biology of the
possible cross-talk between them. It also emphasizes the need to
achieve a complete understanding of the biological role of lysine
site-specific modifications in both endogenous and aggregated
tau, in order to shed light on the molecular events underlying
the pathological transition of tau that characterizes tau-mediated
neurodegeneration.
TAU ACETYLATION
Acetylation is a co- or post-translational modification that is
best known for modifying the N-termini of eukaryotic proteins
(around 85% of human proteins are believed to be N-terminally
acetylated) as well as for modifying the side chains of specific
lysine residues in histones, thereby altering chromatin structure
and providing epigenetic control of transcription. As a result,
the enzymes responsible for acetylating and deacetylating protein
substrates at lysine residues are called histone acetyltransferases
and histone deacetylases, respectively, but given the fact that a
variety of other proteins except for histones can be acetylated
the terms lysine acetyltransferase (KAT) and lysine deacetylase
(KDAC) are more precise. The source of the acetyl group in
protein acetylation reactions is acetyl-CoA and it has been
demonstrated recently byMin et al. (2010), that lysine side chains
of tau protein can be acetylated (Figure 2A). NMR analysis of
recombinant human tau acetylated enzymatically in vitro has
shown that tau displays an overall acetylation level of 6± 2 acetyl
groups per molecule (Kamah et al., 2014). Tau can be acetylated
by either the protein p300 or the CBP acetyltransferase, a CREB-
binding protein and close homolog of the p300 acetyltransferase,
and deacetylated by the NAD+-dependent sirtuin 1 deacetylase
(SIRT1; Min et al., 2010). A decrease in the levels of both SIRT1
mRNA and protein has been associated with enhanced PHF-tau
accumulation in AD patients (Julien et al., 2009), thus indicating
a negative correlation between the regulation of SIRT1 and tau
accumulation.Moreover, histone deacetylase 6 (HDAC6), located
mainly in the cytoplasm, has been shown to interact with tau in
the MBD (Ding et al., 2008) suggesting that HDAC6 is another
possible tau deacetylase, and Cook et al. found that HDAC6 could
deacetylate tau on KXGS motifs (Cook et al., 2014). HDAC6
has also been shown to be involved in assisting the clearance
of misfolded huntingtin through autophagic degradation by
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FIGURE 1 | (A) Endogenous tau is a highly soluble protein adopting an “unfolded” conformational state and consisting of two major domains: the projection domain
that projects from microtubules and the microtubule (MT)-assembly domain that interacts with tubulin heterodimers. Tau can also be divided into four regions: the
N-terminal region, the proline-rich (Pro-rich) region, the microtubule-binding domain (MBD) and the C-terminal region. (B) Tau is responsible mainly for stabilizing
neuronal microtubules based on its phosphorylation state. Abnormal tau hyperphosphorylation weakens tau affinity for microtubules and, thus, releases tau in the
cytosol and destabilizes the microtubule bundles. Unbound hyperphosphorylated tau assembles into pathogenic inclusions that deposit in brain tissues causing
pathological phenotypes.
mediating the retrograde transport of autophagic components to
huntingtin aggresomes (Iwata et al., 2005), supporting the notion
that HDAC6 might act to protect neurons against abnormal tau
rather than act only as a tau the deacetylase. In contrast to
HDAC6, both p300 and SIRT1 are localizedmainly in the nucleus
(Michishita et al., 2005; Blanco-Garcia et al., 2009), whereas tau
resides predominantly in the axonal cytoplasm (Binder et al.,
1985); if they are to regulate tau acetylation exclusively and
directly then the mechanisms underpinning the migration of
these deacetylases to the cytosolic compartment of adult neurons
need to be established.
Remarkably, tau also has intrinsic acetyltransferase activity
and, hence, can catalyze its own acetylation by using cysteine
residues in the MBD—C291 and C322 (all amino acid numbers
in the manuscript refer to human tau) in the R2 and R3 repeats,
respectively—as intermediates to enable transfer of the acetyl
group from acetyl-CoA to certain lysine residues both intra- and
inter-molecularly (Cohen et al., 2013). Different tau isoforms
may have different tendency to undergo autoacetylation, with 4R
isoforms displaying higher levels of autoacetylation compared
to 3R isoforms, which lack the R2 repeat that includes C291
hence contain only the C322 residue (Cohen et al., 2016). Despite
the intrinsically disordered nature of tau, both C291 and C322
residues participate in α-helical structures, which ensures a
relatively ordered conformation and brings cysteine and lysine
residues (C291 and K274, C322 and K340) into close proximity
for the chemical reaction(s) to take place (Luo Y. et al., 2014).
Since acetylated tau is unable to bind to microtubules (Cohen
et al., 2011), it has been suggested that tau autoacetylation might
serve as an autoinhibitory mechanism to prevent interaction
between tau and microtubules (Cohen et al., 2013). Tau self-
acetylation has also been shown to induce tau autoproteolysis,
catalyzed by the same cysteine residues, during which about 17
kDa and 12 kDa C- and N-terminal fragments, respectively, are
generated (Cohen et al., 2016). Mass spectrometry analysis of
the N-terminal end of each fragment identified that the putative
autocleavage sites on tau are located within the R2 and R4 repeats
(Cohen et al., 2016).
Most lysine residues that are putative sites of acetylation
are distributed in the MBD, whilst, a few are found in the N-
terminal and C-terminal regions (Figure 3A). Proteomic studies
revealed 23 lysine residues throughout the tau sequence that can
potentially be acetylated by p300 in vitro, of which 13 lysines
are found in the MBD (Min et al., 2010). NMR analysis assigned
several lysine residues as potential CBP-catalyzed acetylation sites
in accordance with previous mass spectrometric data, including
two novel highly acetylated lysines, K240 and K294 (Kamah
et al., 2014). Acetylation of K163, K174 and K180, located in the
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FIGURE 3 | Tau lysine-specific sites that are modified post-translationally based on the longest human tau isoform. The modified sites include the total number of
sites that have been identified both in vivo and in vitro, in normal tau as well as in pathological states of tau. (A) Tau acetylation sites. (B) Tau methylation sites. (C) Tau
ubiquitylation sites. (D) Tau SUMOylation site. (E) Tau glycation sites.
proline-rich region, has also been confirmed in vivo (Min et al.,
2010). A further study detected K163 in the proline-rich region,
K280 and K281 in the second repeat region and K369 in theMBD
as the major sites of tau acetylation (Cohen et al., 2011). Recently,
13 putative lysine sites were discovered in vivo including K343
and K347 in the MBD (Morris et al., 2015)—acetylation in this
region could affect the affinity of tau for microtubules.
Of the putative acetylation sites, K174, K274, K280, and K281
have received most attention concerning their significance in
regulating tau function. Acetylation of K280 is of particular
interest since it has been suggested to be a critical event for the
formation of pathogenic tau based on data showing that this
modification decreases microtubule binding and, also, precedes
and possibly enhances tau fibrillization into PHFs (Irwin et al.,
2012). Moreover, transgenic Drosophila models overexpressing a
mutant form of human tau (K280Q) to mimic acetylation show
increased phosphorylation at S262 and T212/S214 and enhanced
tau levels, possibly due to either increased oligomerization or
differential protein degradation, thus suggesting that acetylated
K280 contributes to pathological events underlying tau toxicity
(Gorsky et al., 2016). Conversely, examining the co-localization
of acetylated K280 immunoreactivity with multiple tau epitopes
in AD revealed a possible sequence of events, according to which
tau hyperphosphorylation occurs before tau acetylation at K280,
which is then followed by subsequent tau truncation (Irwin
et al., 2012). Notably, immunohistopathological studies revealed
that in normal brains K280 is not identified to be acetylated,
whereas it is predominantly detected in NFTs and, to a lesser
extent, in neuropil threads or pretangles (Cohen et al., 2011;
Irwin et al., 2012). Acetylated K280 is detected in neuronal
and glial inclusions in many tauopathies, such as argyrophilic
grain disease, sporadic and familial AD, frontotemporal dementia
with parkinsonism-17, corticobasal degeneration and progressive
supranuclear palsy (Cohen et al., 2011; Irwin et al., 2012, 2013).
However, Pick’s disease is a 3R tauopathy and 3R tau isoforms
lack exon 10, where K280 is located, so that a low degree of
acetylated K280 was found only in a subset of 4R tau containing
lesions (Irwin et al., 2013). This indicates that acetylation of K280
is not sufficient for causing tau-induced neurotoxicity.
In contrast to K280, acetylated K274, located in the first
repeat region, was shown to be present in neuronal and
glial inclusions of both 3R and 4R human tauopathies from
a variety of sporadic as well as familial cases, with the
exception of the 4R tauopathy argyrophilic grain disease
(Grinberg et al., 2013). Pathological acetylation of K274, as
well as K281, has been reported to cause downregulation of
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the cytoskeletal protein network of the axon initial segment
leading to destabilization of the microtubule barrier in this
region and consequent somatodendritic mis-sorting of tau,
which represents an early event of neurodegeneration (Sohn
et al., 2016). Apart from enabling tau mislocalization, these
modifications have been associated with synaptic dysfunction
and memory deficits observed in AD brains (Tracy et al.,
2016) with possible mechanisms involving the kidney/brain
protein, a postsynaptic memory-associated protein. Specifically,
primary hippocampal neurons expressing K274/K281-specific
acetylation-mimic mutants failed to recruit AMPA receptors
to the postsynaptic surface of spines, whilst activity-dependent
postsynaptic actin polymerization was disrupted; site-specific
acetylated tau was shown to disturb the postsynaptic distribution
of kidney/brain protein, which contributes to impaired actin
polymerization and trafficking of AMPA receptors in the
postsynaptic membrane (Tracy et al., 2016). Lastly, another
significant residue that can be acetylated is K174 found in the
proline-rich region. Pseudoacetylation at K174 (K174Q) was
reported to attenuate tau clearance resulting in increased tau
accumulation and was sufficient to induce behavioral deficits
in vivo, such as memory and learning impairments. Thus,
acetylation of K174 is likely to be an additional key modification
regulating tau-induced toxicity (Min et al., 2015).
The finding that tau can be acetylated gave rise to further
research studies examining the impact of these modifications on
tau physiopathology. In general, acetylation that is elevated by
cellular stress, such as Aβ accumulation (Min et al., 2010), seems
to affect tau biology via two different processes. The first involves
the dysregulation of tau homeostasis due to prevention of
degradation mediated by the ubiquitin-proteasome system (UPS;
Min et al., 2010). Most of the putative acetylated lysine residues
that are distributed in the MBD can also be polyubiquitylated
(see below) to mark tau for degradation (Morris et al., 2015).
Hence, acetylation of lysines can prevent their polyubiquitylation
resulting in insufficient turnover of both endogenous and
hyperphosphorylated tau (Min et al., 2010). Primary cultured
neurons lacking SIRT1 activity that, as a result, show enhanced
acetylated tau levels, also have impaired tau turnover (Min et al.,
2010). Similarly, inadequate turnover of hyperphosphorylated
tau is observed when tau also becomes hyperacetylated (Min
et al., 2010). Impaired clearance of tau is believed to be one of
the major factors that leads to tau accumulation by increasing the
pool of tau available for aggregation by maintaining proteins that
should be normally degraded.
The second mechanism by which acetylation is suggested
to change tau function is through the impairment of tau-
microtubule interactions (Cohen et al., 2011), since acetylation
neutralizes the positive charge of lysine residues in the MBD,
thereby disabling tau binding to negative charges on the
microtubule surface (Luo Y. et al., 2014). Of course, the release
of tau frommicrotubules might act collaboratively with impaired
tau degradation in enhancing tau pathological accumulation.
Nevertheless, whether acetylation facilitates tau fibrillization
remains to be elucidated. However, acetylation of KXGS motifs
(K259, K290, K312, and K353) has been reported to prevent tau
phosphorylation at these same motifs and decreases aggregation
of recombinant tau in vitro (Cohen et al., 2011; Cook et al., 2014).
Furthermore, KXGS motifs are hypoacetylated in AD brains and
in a mouse model of tauopathy (Cook et al., 2014). This discovery
implies that acetylation of particularly KXGS motifs is an event
possibly occurringmerely in normal tau, but its role needs further
investigation. In any case, the fact that other MAP proteins,
such as MAP2, which share highly conserved repeats with tau,
undergo lysine acetylation in the MBD and cysteine-dependent
autoacetylation indicates that acetylation might be a conserved
regulatory mechanism of MAP activity in governing cytoskeletal
dynamics (Hwang et al., 2016).
TAU METHYLATION
Methylation refers to the enzymatic addition of one or more
methyl groups to protein substrates. Typically, the methyl
group derives from S-adenosyl methionine and it is added to
the terminal amino group of lysine or arginine side chains
of the target protein. Depending on the residue that is
modified, lysine methyltransferases (KMTs) and protein arginine
methyltransferases, respectively, are responsible for methylating
the protein substrates; accordingly, the reverse reaction can
be catalyzed by several lysine demethylases (KDMs), but no
arginine demethylases are yet known. Lysine methylation of tau
(Figure 2B) is a relatively recent discovery that, to date, has not
received the same attention as acetylation. Mass spectrometric
analysis of PHFs derived from AD brains showed that several
lysine residues, distributed in the projection domain and MBD
of tau protein, can be methylated (Thomas et al., 2012). So far,
the specific enzymes involved in tau methylation have not been
identified.
Lysine methylation has been detected in tau protein isolated
from both pathological and normal brains (Figure 3B). In human
AD brains, aggregated tau is monomethylated at seven lysine
residues found in the proline-rich region and the R1 and R2
repeats within the MBD, of which K180 and K267 appear to be
more frequently methylated, in contrast to K290 that displays
the lowest level of methylation (Thomas et al., 2012). Later
studies showed that endogenous tau from cognitively-normal
human brains can be monomethylated as well as dimethylated
at different lysine residues (Funk et al., 2014; Morris et al., 2015).
Extracted soluble tau is methylated at up to 11 sites, more than
found to be modified in PHF-tau, and which are distributed
throughout the sequence, whilst in vitro reductive methylation
of recombinant tau led to detection of 23 methylated lysines
(Funk et al., 2014). Furthermore, not only lysine residues, but the
arginine residues R126, R155, and R349 were detected as possible
sites of monomethylation in normal mouse tau and in a mouse
model of AD (Morris et al., 2015). Tau modified by the addition
of three methyl groups at a single site—tri-methylation—has not
yet been found in either healthy or pathological states.
Since K254 was found to be mainly methylated and, to
a lesser extent, ubiquitylated (see below) in PHF-tau, it has
been suggested that methylation may block UPS-mediated
degradation of tau leading to a further enhancement of
tau levels in the cell (Thomas et al., 2012). At the same
time, phosphorylation of S262, which reduces tau affinity for
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microtubules, is found more frequently in the presence of
methylated K267 in PHF-tau (Thomas et al., 2012). This suggests
that lysine methylation, apart from preventing degradation by
the UPS, might result in abnormal phosphorylation of tau. In
addition, most of the potentially methylated sites of PHF-tau are
subject to acetylation as well, suggesting that these modifications
might compete for the same site-specific lysine residues on
pathological tau. K163, K174 and K180 were identified in vivo
as possible sites of both acetylation and methylation (Min et al.,
2010; Thomas et al., 2012), thus signifying the importance to
explore the competing factors that may govern tau pathological
modifications. However, significant putative acetylated sites, such
as K280 and K281, have not yet been detected as beingmethylated
(Thomas et al., 2012).
Immunohistochemical studies using a combination of a
polyclonal antibody, that recognizes methylated tau epitopes,
and antibodies specific for epitopes present on PHF-tau
demonstrated that methylated tau is highly colocalized with
NFTs especially in late-stage AD brains (Thomas et al., 2012).
Given that the regions found to be potentially methylated in
pathological tau are essential for interactions with microtubules
and other partners, lysine methylation may serve to suppress
tau binding to these partners. Moreover, lysine residues have
been shown to participate in electrostatic interactions facilitating
abnormal protein aggregation (Sinha et al., 2011) and, as a
result, it has been suggested that methylation of lysine residues
possibly enables interactions between tau molecules, playing thus
an important role in tau self-assembly and NFT formation. This
is further supported by the discovery that lysine methylation of
other non-histone proteins, such as the transcription factor p53,
affects both protein-protein interactions and protein stability
(West and Gozani, 2011). In contrast, although the impact
of lysine methylation on endogenous tau activity remains
unknown, recombinant tau methylated in vitro via reductive
methylation appeared to have low tendency for aggregation and
the modifications actually promoted tubulin assembly (Funk
et al., 2014), indicating that methylation of tau might have a
protecting role against abnormal aggregation of the protein.
However, the specificity of a chemically-induced modification
is generally low, making it difficult to interpret its effects on
tau. Therefore, an extensive investigation of the site-dependent
lysine methylation observed in vivo would contribute to the
understanding of this modification in tau biology.
TAU UBIQUITYLATION
Ubiquitylation involves the formation of an isopeptide bond
between the C-terminal carboxyl group of the small regulatory
protein ubiquitin and the ε-amino group present in lysine side
chains of proteins (Figure 2C). Sequential addition of more than
one ubiquitin molecule by ubiquitin-chain elongation factors
(E4 polyubiquitin ligases) can result in the generation of long
polyubiquitin chains, which differ in terms of the specific lysine
residue that is used to form an isopeptide bond to the C-terminal
glycine of the next ubiquitin molecule defining, therefore, the
type of polyubiquitin linkage. In general, it is polyubiquitylation
rather than the attachment of a single ubiquitin that acts to
induce the proteolytic degradation of targeted proteins in the
cytoplasm by the UPS, but different types of polyubiquitin
linkage affect the fate of the modified protein in various
ways. Whereas, K48-polyubiquitylated proteins are degraded
by the UPS pathway with the help of Rad23 proteins, which
stimulate their binding to the proteasome (Nathan et al., 2013),
K63-polyubiquitylated proteins are directed to the lysosomal-
autophagic pathway. K63 polyubiquitin chains were shown to
interact selectively with the cellular factor ESCRT0 (Endosomal
Sorting Complex Required for Transport), which prevents the
binding to the 26s proteasome (Nathan et al., 2013), permitting
K63-polyubiquitylated proteins to serve different functions, such
as receptor endocytosis, intracellular signaling and DNA repair
(Mukhopadhyay and Riezman, 2007; Ikeda and Dikic, 2008).
Ubiquitylation takes place in three successive stages, each of
them involving a distinct enzyme: an E1 ubiquitin activating
enzyme that catalyzes the ATP-dependent ubiquitin activation,
an E2 ubiquitin conjugating enzyme onto which activated
ubiquitin is transferred through a transesterification reaction
and, finally, an E3 ubiquitin ligase essential for catalyzing the
formation of the isopeptide bond between ubiquitin’s terminal
glycine and the target protein. Amongst these, the E3 ubiquitin
ligase primarily defines the specific protein substrate that will be
ubiquitylated.
Enzymes Regulating Tau Ubiquitylation
Several E3 ligases have been reported to ubiquitylate tau,
including the C-terminus of the Hsc70-interacting protein
(CHIP), TNF receptor-associated factor 6 (TRAF6) and
axotrophin/MARCH7 (Petrucelli et al., 2004; Babu et al., 2005;
Flach et al., 2014), whereas other E3 ubiquitin ligases, such
as parkin and Cbl, failed to ubiquitylate hyperphosphorylated
tau (Petrucelli et al., 2004; Shimura et al., 2004). CHIP was
shown to ubiquitylate tau in vivo and in vitro by associating
with tau’s MBD and the nearby proline-rich region, thereby
promoting the proteasome-mediated degradation of soluble tau
(Petrucelli et al., 2004). CHIP has intrinsic E3 ubiquitin ligase
activity via a U-box domain, and ubiquitylates tau through
K48 or K63 linkages (Petrucelli et al., 2004). Two types of E2
ubiquitin conjugating enzymes, UbcH5a and Ubc13-Uev1a,
have been identified to interact with CHIP, but it is likely
that the sequential interaction of Ubc13-Uev1a with other E2
enzymes is responsible particularly for ubiquitylating tau with
K63 polyubiquitin chains (Xu et al., 2008). It has also been
reported that hyperphosphorylated tau derived from AD brains
can be polyubiquitylated by use of HbcH5B as an E2 enzyme
(Shimura et al., 2004). CHIP might mediate tau degradation
in both physiological and diseased conditions regardless
of its phosphorylation state (Zhang et al., 2008), however,
tau hyperphosphorylation was shown to be a recognition
requirement for ubiquitylation by the CHIP-Hsc70 complex in
the presence of HbcH5B (Shimura et al., 2004).
CHIP interacts directly with the molecular chaperone
Hsp70/Hsp90 and increased Hsp70 activity in HEK293 cells
was found to weaken CHIP activity, thereby suppressing CHIP-
mediated tau ubiquitylation; given that Hsp70 interacts with
tau this suggests an antagonistic relationship between the two
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interacting partners (Petrucelli et al., 2004). A quantitative
analysis of CHIP in human and mouse brains revealed that the
levels of CHIP andHsp70 appear to be increased in AD compared
with normal controls (Sahara et al., 2005). Also, in several human
tauopathies, CHIP localized to tau neuronal and glial lesions,
with 3R tauopathies displaying more CHIP immunoreactivity
than 4R or 3R+ 4R tauopathies (Petrucelli et al., 2004). Increased
accumulation of aggregated tau species was observed in a cell
culture system overexpressing CHIP (Petrucelli et al., 2004). In
contrast, insoluble tau accumulation has been increased in a
mouse model lacking CHIP (Sahara et al., 2005). These data
suggest that the CHIP-Hsp70 complex might be a key molecular
assembly affecting tau pathogenic events, but its role needs
further investigation.
CHIP may also affect abnormal tau levels indirectly via two
possible processes. Firstly, it has been demonstrated that CHIP
ubiquitylates and controls the levels of HDAC6, a deacetylase
of the molecular chaperone Hsp90, and enhanced levels of
HDAC6 have been associated with augmented tau accumulation
(Cook et al., 2012). The second pathway involves a different
stress-induced substrate of CHIP, the cellular kinase Akt, which
prevents CHIP-induced tau ubiquitylation and its subsequent
degradation by regulating the CHIP-Hsp90 complex directly,
competing with tau for binding to CHIP or promoting tau
hyperphosphorylation at S262/S356, a tau species that is not
recognized by the CHIP-Hsp90 complex (Dickey et al., 2008).
Another candidate E3 ubiquitin ligase for tau is TRAF6,
which ubiquitylates tau via K63 linkages, apparently inducing
tau degradation through the UPS pathway (Babu et al., 2005).
Although, K63 polyubiquitylation has not been associated
with proteolytic degradation of substrates by the UPS, the
26s proteasome is capable of binding and degrading K63-
polyubiquitylated proteins in vitro in a similarly way to proteins
modified by K48-polyubiquitin chains (Hofmann and Pickart,
2001). In aggregates extracted from AD brains TRAF6 was
shown to be colocalized with the ubiquitin-associating protein
sequestosome 1/p62, a cellular protein responsible for interacting
with the proteasomal subunit Rpt1 (Babu et al., 2005). p62
interacts with the K63 polyubiquitin chain of tau through its UBA
domain (Babu et al., 2005), so is suggested to be an essential
intermediate of TRAF6-mediated tau degradation.
Recently, by use of yeast-two-hybrid systems it was shown
that axotrophin/MARCH7 is a tau-interacting protein and, also,
has E3 ligase activity via its C-terminal RING-variant domain
in the presence of the E2 enzymes UbcH5b/c, UbcH6 and, to
a lesser extent, UbcH13 (Flach et al., 2014). Axotrophin is able
to induce tau monoubiquitylation in vitro with tau isoforms
being preferentially modified at multiple sites, including some
located in the MBD, which led to weakened tau binding to
microtubules (Flach et al., 2014). In AD brain tissues, axotrophin
was observed to colocalize with tau aggregates in different cellular
compartments, such as the cell soma or dendrites, in contrast
to normal brains and tau knockout mice, where axotrophin was
found predominantly in the nucleus implying that tau affects the
intracellular sorting of axotrophin (Flach et al., 2014).
Ubiquitylation is a reversible process with specific
deubiquitinases (DUBs), catalyzing the cleavage of the isopeptide
bond. So far, only Otub1, a cysteine protease deubiquitinating
enzyme, has been reported to deubiquitinate endogenous tau
in mouse brains and prevent tau degradation by removing
K48 polyubiquitin chains (Wang et al., 2017). Using primary
neurons derived from a tau transgenic mice model, it was
shown that Otub1 expression leads to increased total tau levels
confirming the role of Otub1 as a tau deubiquitinating enzyme
and suggesting that impairment of Otub1 expression could result
in impaired tau clearance (Wang et al., 2017). Furthermore,
Otub1 was shown to contribute directly to tau pathology,
since Otub1 expression in primary neurons leads to enhanced
tau aggregation and increased levels of oligomeric tau forms
(Wang et al., 2017), which might be important given that tau
oligomers have emerged as the pathogenic species in tauopathies
(Lasagna-Reeves et al., 2010).
Putative Ubiquitylated Sites on Tau
Mass spectrometric analysis of soluble PHF-tau immunopurified
from AD brains revealed three putative ubiquitylated lysine
residues: K254 and K353 located in the R1 and R4 repeat
sequences, respectively, and K311 found in the flanking region
between the R2 and R3 repeat sequences (Figure 3C; Cripps
et al., 2006). K290, another lysine residue located within the
MBD, was detected to be ubiquitylated in a mouse model of AD
(Morris et al., 2015). Endogenous murine tau is ubiquitylated
at 15 possible lysine residues, which are distributed mostly
throughout the MBD region, except for K44 that is found
in the N-terminal region (Morris et al., 2015); some of these
residues are subject to methylation as well. For example, K254
from PHF-tau isolated from late-stage AD regions is either
ubiquitylated or methylated, with the latter strongly dominating
(Thomas et al., 2012). Moreover, to date all of the lysine
residues discovered to be possibly ubiquitylated are sites that
could be acetylated as well. These discoveries suggest that
some modifications occur at the expense of others indicating
even more strongly the importance to clarify the site-specific
biochemical cross talk between competing post-translational
modifications. Furthermore, mass spectrometric data identified
three types of polyubiquitin linkage through which PHF-tau is
modified, K6, K11 and, predominantly, K48 linkages (Cripps
et al., 2006), whereas soluble tau can also be ubiquitylated via
K63 polyubiquitin conjugation (Petrucelli et al., 2004). Notably,
coexpression of K63 ubiquitin with a disease-associated tau
mutant in SH-SY5Y neuroblastoma cells enhanced the formation
of ubiquitin-enriched tau-positive inclusions (Tan et al., 2008).
The Effect of Ubiquitylation on Tau Biology
The studies concerning the role of tau ubiquitylation in its
degradation are rather controversial. Tau can be proteolytically
processed by the proteasome through an ubiquitin-dependent
process, but, since tau is a natively unfolded protein, it was shown
that normal tau degradation might not require its preceding
ubiquitylation at all (David et al., 2002; Petrucelli et al., 2004;
Grune et al., 2010). At the same time, the contribution of tau
ubiquitylation in tau pathology has not been completely clarified.
Ubiquitin was identified as a protein component of PHFs, NFTs
and neurites associated with senile plaques in the brains of
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patients with AD (Mori et al., 1987; Perry et al., 1987), which
appeared to includemore ubiquitin compared to normal controls
(Riederer et al., 2009). However, given that pre-tangles were
not immunostained by an anti-ubiquitin antibody, this suggests
that ubiquitin might be linked to fibrillary inclusions only
after their formation (Bancher et al., 1991; Garcia-Sierra et al.,
2012). Similarly, the ends of neuropil threads, which represent
newly formed regions, are characterized by the absence of anti-
ubiquitin immunostaining (Iwatsubo et al., 1992). Moreover,
abnormal hyperphosphorylation and N-terminal cleavage of
tau was shown to precede both the formation as well as the
ubiquitylation of tau neurofibrillary inclusions in AD brains
(Bancher et al., 1991; Morishima-Kawashima et al., 1993). In
contrast, it was reported that both monoubiquitylation and
polyubiquitylation contribute to the formation of insoluble
protein inclusions present in neurodegenerative diseases (Dickey
et al., 2006; Tan et al., 2008) and, as mentioned above, increased
aggregation of tau was detected in a cell culture overexpressing
CHIP (Petrucelli et al., 2004) implying that ubiquitylation
enhances the formation of these aggregates.
Since tau was identified as the ubiquitin-targeted protein
in PHFs (Morishima-Kawashima et al., 1993), this has raised
questions about the insufficient clearance of pathological
fibrillary inclusions of tau. Apart from inaccessibility of the
ubiquitylated tau aggregates by the cellular quality control
system, the inhibitory binding of PHF-tau to proteasomes is
responsible for the proteasomal impairment observed in AD
brains (Keck et al., 2003). Additionally, most ubiquitin found
in PHFs from AD brains occurs as a monoubiquitylated form,
whereas only a small proportion of ubiquitin forms polyubiquitin
chains (Morishima-Kawashima et al., 1993), making it difficult
to induce UPS-mediated proteolysis of tau aggregates. Another
aspect demanding further investigation is the role of the
autophagic pathway in removing insoluble tau structures since
truncated tau present in AD brains is reported to be preferentially
cleared by the autophagic pathway (Rissman et al., 2004; Dolan
and Johnson, 2010).
Since impaired tau clearance is widely considered to be
a critical factor causing tau accumulation in neurons, many
therapeutic approaches targeting tau pathology aim to promote
either ubiquitylation or degradation of tau protein. Long-
term administration of lithium to murine models of AD-like
tauopathies reduces tau lesions primarily by enhancing their
ubiquitylation (Nakashima et al., 2005), whereas synthesis of
molecules that bring tau and E3 ubiquitin ligases together
aims to enhance tau polyubiquitylation and degradation
(Chu et al., 2016). Lastly, specific RNA aptamers of USP14,
a proteasome-associated deubiquitylating enzyme, inhibited
the deubiquitylating activity of this enzyme facilitating the
proteasomal degradation of tau in vitro (Lee et al., 2015).
TAU SUMOYLATION
SUMOylation is another modification in which a small protein
is post-translationally attached to the target protein. An
ubiquitin-like protein, the small ubiquitin-likemodifier (SUMO),
is transferred enzymatically to the terminal amino group of lysine
side chains of the target protein forming an isopeptide bond in
a way similar to ubiquitylation (Figure 2D). Three main SUMO
isoforms are expressed in cells, SUMO1, SUMO2, and SUMO3, of
which SUMO2 and SUMO3 are more similar to each other than
to SUMO1 (Sarge and Park-Sarge, 2009).
Analysis of immunoreactive tau species derived fromHEK293
cells expressing tau and different His-tagged SUMO isoforms
showed that tau is preferentially monoSUMOylated by SUMO1
and, to a lesser extent, by SUMO2 and SUMO3 (Dorval and
Fraser, 2006). Like ubiquitin, SUMO is conjugated by an ATP-
dependent enzymatic cascade involving an E1 activating enzyme,
an E2 SUMO-conjugating enzyme and an E3-type SUMO ligase.
The AOS1-UBA2 complex acts as an E1 activating enzyme, whilst
Ubch9 has E2 SUMO-conjugating activity (Desterro et al., 1997;
Gong et al., 1999), although there is as yet no direct evidence that
they are responsible for tau SUMOylation. Like ubiquitylation,
SUMOylation is a reversible process, since specific proteases,
called SENPs, can rapidly remove SUMO from their substrates.
Although the SENP3 protease was reported to be downregulated
in AD tissues (Weeraratna et al., 2007), as with SUMOylation
enzymes, no particular proteases have been identified specifically
to deSUMOylate tau.
Lysine residues that are targeted for SUMOylation are part
of the consensus motif 9KX(E/D), where 9 and X represent a
hydrophobic residue and any amino acid, respectively, (Dorval
and Fraser, 2006). Tau contains two such motifs, VK340SE and
AK385TD, however, the examination of SUMOylation at these
lysine sites by generating the tau mutants K340R and K385R
showed that only K340R displays altered SUMOylation levels
indicating that K340, located within the MBD, is the major
SUMOylation site on tau (Figure 3D; Dorval and Fraser, 2006).
Another study that also used the K340R mutation showed that
the effect of tau SUMOylation on HEK293 cells co-transfected
with SUMO1 and tau K340R is eliminated, confirming that
K340 is indeed a putative SUMOylation site (Luo H. B.
et al., 2014). Between valine and alanine, valine displays higher
hydrophobicity, potentially explaining why the motif VK340SE
might form a more appropriate environment than AK385TD for
facilitating the SUMOylation of the included lysine residue.
Tau is available for SUMOylation only after its release
from microtubules (Dorval and Fraser, 2006) suggesting that
SUMOylation is a post-translational modification that does not
target the endogenous tau pool but, consequently, is likely
to be involved exclusively in tau pathogenic processes. This
agrees with evidence showing that tau hyperphosphorylation,
which is the main trigger of tau unbinding from microtubules,
facilitates SUMOylation by SUMO1 in HEK293 cells (Luo
H. B. et al., 2014). Although hyperphosphorylation possibly
precedes SUMOylation, there is increased evidence that tau
SUMOylation reciprocally enhances tau hyperphosphorylation
at several AD-related sites, such as T231 and S262 (Luo H. B.
et al., 2014). SUMOylation also modulates tau ubiquitylation;
SUMOylation of hyperphosphorylated tau at K340 inhibits
its ubiquitylation and the subsequent proteasome-dependent
degradation (Luo H. B. et al., 2014). In contrast, inhibition of the
proteasome pathway stimulates tau ubiquitylation, whereas tau
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SUMOylation is eliminated (Dorval and Fraser, 2006). Possible
reasons explaining why tau SUMOylation affects ubiquitylation
and vice versa is that conjugation of a polypeptide group
may inhibit the attachment of another large molecule to the
neighboring lysine residues by steric factors or that these two
tau modifications compete for the same lysine residues on tau,
even though the only putative SUMOylated site, K340, was not
identified to be ubiquitylated. SUMOylation could be a factor
contributing to the impaired clearance of tau under pathological
conditions by upregulating the pool of pathogenic tau in the
cytosol and enhancing tau aggregation due to the decreased
solubility of SUMOylated tau (Luo H. B. et al., 2014).
Immunohistochemical analysis of brains fromAPP transgenic
mice, a model of AD, revealed that SUMO1 co-localizes with
hyperphosphorylated tau in neurites associated with amyloid
plaques suggesting that tau SUMOylation is a downstream
effect mediated by pathological Aβ amyloid plaques (Takahashi
et al., 2008). In agreement with this observation, rat primary
hippocampal neurons displayed increasing levels of tau
SUMOylation when treated with increasing concentrations of
Aβ peptides (Luo H. B. et al., 2014). In the Tg2576 murine model
of AD, SUMO1 protein conjugation was elevated both in the
cortex and hippocampus (Nistico et al., 2014). Conversely, NFTs
found in the brains of AD patients and hyperphosphorylated
tau inclusions from mutant tau transgenic mouse brains
were both negative for SUMO1 immunoreactivity (Takahashi
et al., 2008). In progressive supranuclear palsy brain tissues,
SUMO1 colocalizes within perinuclear tau-positive inclusions
in oligodendrocytes and labels lysosomes in oligodendrocytes
containing tau inclusions, in contrast to those where tau
aggregates are absent (Wong et al., 2013). This finding indicates
that SUMOylation might be involved in the autophagy-lysosome
pathway in tauopathies, but this remains to be elucidated. What
is more, increased SUMO1 levels were determined by ELISA in
blood plasma derived from both dementia and mild cognitive
impairment patients compared to healthy samples suggesting
that SUMO1 could serve as an AD biomarker (Cho et al., 2015).
Recently, a SUMO1 transgenic mouse model with SUMO1
overexpression in neurons was generated, in which increased
levels of SUMO1 eliminated basal synaptic transmission,
impaired presynaptic function and reduced spine density, which
resulted in learning and memory deficits (Matsuzaki et al., 2015).
Since tau is an important SUMO1 target in the cytoplasm and
dendritic spines it would be intriguing if hyper-SUMOylation of
tau underpinned these deficits, although there are clearly other
molecular targets that require follow up.
TAU GLYCATION
Glycation (or non-enzymatic glycosylation) defines the non-
specific reaction in which reducing sugars, especially glucose,
are non-enzymatically linked to proteins by condensation of a
sugar aldehyde or ketone group with terminal amino groups of
lysine side chains (Figure 2E). As a result, glycation depends
on both the availability of free lysine amino groups along the
polypeptide chain and the concentration of sugar. The glycation
products are subject to further changes that lead to the formation
of the advanced glycation end products (AGEs) by developing
irreversible cross-links with other proteins over a long period
of time (Eble et al., 1983). Although, the formation of AGEs
does not involve enzymes, there are several enzyme systems that
antagonize AGEs production, like the NADPH-dependent aldose
reductase and the aldehyde dehydrogenase (Li J. et al., 2012).
Non enzymatic glycation is one of the modifications detected
in PHF-tau purified from human AD brains in vivo, but not
in soluble tau (Figure 3E; Ledesma et al., 1994). It occurs
preferentially at the MBD of PHF-tau (Ledesma and Avila,
1995); lysines present at the R3 repeat were initially identified
to be glycated in vitro (Ledesma et al., 1994), but later studies
confirmed immunologically that glycation takes place in vivo
within the MBD (Ledesma and Avila, 1995). 13 lysine residues,
located throughout the polypeptide chain, were also identified as
being glycated in vitro (Nacharaju et al., 1997); although most
of these sites were detected in both 3R and 4R isoforms, K280
and K281 are absent in the case of 3R tau and this difference
seems enough to cause slower glycation of 3R compared to
4R isoforms (Nacharaju et al., 1997; Liu et al., 2016). Recently,
mass spectrometry analysis revealed 19 novel sites of glycation
occurring on recombinant full length tau (Liu et al., 2016).
Since tau has been shown to be glycated within the
MBD and glycated tau appears to have reduced affinity for
microtubules in vitro, it has been suggested that glycation
blocks tau-microtubule interactions, thereby assisting tau
hyperphosphorylation (Ledesma et al., 1994). The region of
tau containing the MBD was shown to participate in its self-
association (Ledesma and Avila, 1995), implying that glycation
indirectly facilitates the aggregation of tau or stabilizes the
aggregated tau species. On the other hand, since glycated PHF-
tau has higher tendency for aggregation compared to non-
glycated soluble tau, it is likely that glycation stimulates the
aggregation of PHFs into more complex structures and stabilizes
the assembled formations (Ledesma et al., 1994, 1996; Ko et al.,
1999). This suggestion is supported by the observed crosslinking
between AGE-modified proteins, which represents an additional
factor contributing to the insolubility and resistance against
proteolytic degradation that are characteristic of tau aggregates.
However, tau glycation enhances, but is not able to trigger,
aggregation in vitro (Necula and Kuret, 2004). In addition,
glycation has different impacts on aggregation propensity
depending on the tau isoform that is modified, with the full length
tau isoform displaying more extensive aggregation when glycated
(Liu et al., 2016).
By immunoelectron microscopy, AGEs were found to
colocalize with PHF-tau in NFTs of sporadic AD (Yan et al.,
1994). Intracellular AGE-positive deposits were found to
correlate positively both with age in normal and AD cases
and with the stage of the disease in AD patients (Luth et al.,
2005). AGEs may be involved in several processes underlying
tau pathogenesis; neurons carrying AGE-positive NFTs also bear
intracellular reactive oxygen intermediates (Yan et al., 1994).
Moreover, it has been found that the introduction of glycated
recombinant tau into neuroblastoma cells is able to generate
oxygen free radicals causing neuronal dysfunction by inducing
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oxidative stress (Yan et al., 1994). Further studies demonstrated
that AGEs may be involved in the tau-associated pathogenesis
of AD via reactive oxygen intermediates by activating NF-kB-
induced transcription, which leads to increased expression of the
cytokine IL-6, and by enhancing the synthesis of the amyloid
precursor protein, which, as a consequence, promotes the release
of the Aβ peptides under stress conditions (Yan et al., 1995). By
using reactive carbonyl compounds, which are elevated under
conditions of oxidative stress, enhanced formation of AGE-
modified tau tangles was observed in vivo (Kuhla et al., 2007).
AGEs can also cause cellular toxicity through their receptor
(RAGE). In a mouse model of AD, tau is colocalized with RAGE
in the hippocampus and cortex (Choi et al., 2014) and RAGE has
been associated with AGE-induced tau hyperphosphorylation as
well as synapse dysfunction and spatial memory impairment in
rats (Li X. H. et al., 2012). Lastly, apart from AD, tau-positive
inclusions were also AGE-positive in the case of Pick’s disease as
well as in other neurodegenerative diseases (Sasaki et al., 1998).
CONCLUSION
Lysine residues of tau are common targets for different post-
translational modifications including acetylation, methylation,
ubiquitylation, SUMOylation, and glycation. As a result, it is
likely that modification of a target lysine blocks or controls
other possiblemodifications occurring at the same site. Although,
the identification of possible sites found to be modified is
unlikely yet to be complete, the overlap between each type
of post-translational modification in terms of all lysine sites
that have been discovered so far is obvious, implying that
certain lysine modifications compete for the same site on
tau. At the same time, the high content of lysine residues in
tau provides sufficient targets to be modified emphasizing the
importance of lysine post-translational modification in normal
tau biology as well as the mechanisms of misfolding and
cellular toxicity elicited by it pathogenic isoform(s). Significantly,
the sites modified in vitro might differ from those identified
in in vivo systems, whereas the species, neuronal subtype
and pathological state could promote different site-specific
modifications as well as certain combinations of modified lysine
sites. Therefore, methodical mapping of the lysine residues that
can be modified both on endogenous and abnormal tau under
different pathological conditions is crucial. The impact of each
type of post-translational modification on normal tau or related
to pathological states of tau is likely to be site-dependent and
the potential for cross-talk of these modifications is high—this
fact guides the direction for future scientific research in order
to unravel fully the biochemical mechanisms underpinning tau
biology.
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